Therapy Areas: AIDS & HIV
CBR Touts Positive Results for First Study Administering Cord Blood to Children with Hearing Loss
18 September 2018 - - US-based newborn stem cell company CBR (Cord Blood Registry) has published the results of the first clinical trial evaluating the use of autologous umbilical cord blood...
Virion Names King as President and CEO and Isabel Najera as CSO
17 September 2018 - - UK-based biologicals developer Virion Biotherapeutics has appointed Vanessa King, PhD, as president and chief executive officer and Isabel Najera, PhD, as chief scientific office...
ViiV Healthcare submits European Medicines Agency regulatory application for HIV drug
17 September 2018 - ViiV Healthcare, a UK-based pharmaceutical company and a joint venture between Glaxo Smith-Kline, Pfizer and Shionogi, announced on Friday the submission of a marketing authorisati...
Gollaher Named to Cidara Therapeutics Board of Directors
14 September 2018 - - US-based biotechnology company Cidara Therapeutics, Inc. (NASDAQ: CDTX) has appointed indus David Gollaher, Ph.D., to the company's board of directors, the company said.
MilliDrop Receives EUR 1.9m from Bpifrance to Develop a Rapid Diagnosis Test for Sepsis
12 September 2018 - - France-based MilliDrop, which designs and develops cell culture solutions based on millifluidics technology for bacteriological research and diagnosis purposes, has bee...
US Merck Says Zerbaxa Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
11 September 2018 - - Apivotal Phase 3 clinical study evaluating US-based pharmaceutical company Merck and Co., Inc.'s (NYSE: MRK) antibiotic Zerbaxa (ceftolozane and tazobactam) at an investigat...